companyprofile
Actions
Dallah Healthcare Co.
- Main Market
- Health Care Equipment & Svc
Stats Overview
-
Prev. Close 158.60
-
Open -
-
High -
-
Low -
-
No. of Trades 0
-
Avg. Trade size* N/A
-
Volume Traded 0
-
Value Traded (SAR) 0.00
Performance
- *Average Trade Size = Cumulative / # of Trades
- **52 Week Price Change = (Current Price - Price year ago) / Price year ago x 100
- Historical prices & volume traded data are adjusted to account for all corporate actions.
- MO: Market Order
Trade Updates
Last Trade
Best Bid
Best Offer
52 WEEK
PERFORMANCE
Compare Selected
Select a Maximum of 5 Companies
LoginPortletPopupv2
Actions
AddtoWatchlistv2
Actions
AnnouncmentandCorporateAction
Actions
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Announcements
Corporate Actions
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Dividends
| Announced Date | Eligibility Date | Distribution Date | Distribution Way | Dividend Amount |
|---|---|---|---|---|
| 05/08/2024 | 25/08/2024 | 08/09/2024 | Account Transfer | 0.50 |
| 12/06/2024 | 31/07/2024 | 14/08/2024 | Account Transfer | 0.50 |
| 26/12/2023 | 16/01/2024 | 30/01/2024 | Account Transfer | 0.50 |
| 06/11/2023 | 12/11/2023 | 26/11/2023 | Account Transfer | 0.50 |
| 08/08/2023 | 24/08/2023 | 07/09/2023 | Account Transfer | 0.50 |
CompanyProfilev2Financials
Actions
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Financials
- FINANCIAL INFORMATION
- FINANCIAL STATEMENTS AND REPORTS
- Annually
- Quarterly
| Balance Sheet | 2023-12-31 | |||
|---|---|---|---|---|
| Total Assets |
6,242,854.7
|
- | - | - |
| Total Liabilities |
2,770,202.7
|
- | - | - |
| Total Shareholders Equity (After Deducting the Minority Equity) |
3,203,392.97
|
- | - | - |
| Total Liabilities and Shareholders Equity |
5,973,595.67
|
- | - | - |
| Statement of Income | 2023-12-31 | |||
| Total Revenue (Sales/Operating) |
2,942,897.7
|
- | - | - |
| Net Profit (Loss) before Zakat and Tax |
400,315.32
|
- | - | - |
| Zakat and Income Tax |
-14,890.48
|
- | - | - |
| Net Profit (Loss) after Zakat and Tax |
385,424.84
|
- | - | - |
| Total Comprehensive Income |
392,826.36
|
- | - | - |
| Profit (Loss) per Share |
3.7
|
- | - | - |
| Cash Flows | 2023-12-31 | |||
| Net Cash From Operating Activities |
625,783.84
|
- | - | - |
| Net Cash From Investing Activities |
-293,684.95
|
- | - | - |
| Net Cash From Financing Activities |
-334,736.08
|
- | - | - |
| Cash and Cash Equivalents, Beginning of the Period |
237,944.91
|
- | - | - |
| Cash and Cash Equivalents, End of the Period |
235,307.72
|
- | - | - |
| All Figures in | Thousands | |||
| All Currency In | SAR | |||
| Last Update Date | 2024-05-12 |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate. The above information does not replace detailed financial statements, as detailed financial statements are the reliable source that must be consulted to obtain accurate financial information.
| Balance Sheet | 2023-09-30 | |||
|---|---|---|---|---|
| Total Assets |
6,103,341.13
|
|||
| Total Liabilities |
2,650,476.55
|
|||
| Total Shareholders Equity (After Deducting the Minority Equity) |
3,188,198.8
|
|||
| Total Liabilities and Shareholders Equity |
5,838,675.36
|
|||
| Statement of Income | 2023-09-30 | |||
| Total Revenue (Sales/Operating) |
749,827.77
|
|||
| Net Profit (Loss) before Zakat and Tax |
111,322.55
|
|||
| Zakat and Income Tax |
-4,989.96
|
|||
| Net Profit (Loss) after Zakat and Tax |
106,332.59
|
|||
| Total Comprehensive Income |
111,587.95
|
|||
| Profit (Loss) per Share |
1.01
|
|||
| Cash Flows | 2023-09-30 | |||
| Net Cash From Operating Activities |
355,889.25
|
|||
| Net Cash From Investing Activities |
-158,252.03
|
|||
| Net Cash From Financing Activities |
-292,358.52
|
|||
| Cash and Cash Equivalents, Beginning of the Period |
237,944.91
|
|||
| Cash and Cash Equivalents, End of the Period |
143,223.61
|
|||
| All Figures in | Thousands | |||
| All Currency In | SAR | |||
| Last Update Date | 2024-01-10 |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate. The above information does not replace detailed financial statements, as detailed financial statements are the reliable source that must be consulted to obtain accurate financial information.
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Company Profile
Company overview
The main core business for Dallah Health is hospitals. The company runs its two hospitals. The Hospital provides medical services for its outpatient, inpatients, specialized clinics, and hypnosis departments. Besides hospitals, Dallah health has other business activities: Dallah pharma trade manufactures and distributes the medicines. Dallah health manages and operates other hospitals and provides support services in maintenance for hospitals and medical centers. We also have investments and shares in other companies in the healthcare industry in MENA, in which Dallah health invests heavily in other companies in the health care industry.
Company History
Dallah Health is a joint stock company listed in the Saudi TADAWL since November 2012 under commercial registration: 1010128530 dated September 19 1994 under code number (4004) in the health care Sector''s main market. The company''s capital consists of ninety-seven million, six hundred eighty-one thousand and one hundred sixty-six (97,681,166) ordinary shares. With a nominal value of 10 riyals paid in full and a total value of nine hundred seventy-six million eight hundred eleven thousand six hundred sixty (976,811,660) Saudi Riyals
Company Bylaws
Equity Profile
- Authorized Capital (SAR) 976,811,660
- Issued Shares 97,681,166
- Paid Capital (SAR) 976,811,660
- Par Value/Share 10
- Paid Up Value/Share 10
Last Update :2023-01-16
Investment limits
There are no investment limits on the company shares as per the amended Rules for Qualified Foreign Financial Institutions Investment in Listed Securities and Instructions for the Foreign Strategic Investors Ownership in Listed Companies based on company bylaw and the issued instructions by the related regulators and supervisory authorities
- Company Details
- BOARD OF DIRECTORS AND SENIOR EXECUTIVES INFORMATION
Investor Relations
Contact Name:
Investor Relations
Company Address:
Nakheel building, 1157 King Fahad Road, 2nd fl., Nakheel District, Riyadh, KSA
Contact Details:
Telephone:
0112255065-5001
Fax
: 0114550803
Email
: IR@dallahhealth.com
Company Website:
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of these disclosures, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of these disclosures, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.